Now Reading
Japan Develops Smart Glasses to Correct Myopia

Japan Develops Smart Glasses to Correct Myopia

Kubota Pharmaceutical Holdings, a Japanese company, is developing smart glasses that correct myopia over time.

The company believes it is possible to slowly but effectively improve vision. This, of course, without resorting to corrective surgery. Therefore, Kubota has designed a device that, once placed in front of the patient’s eyes, as with conventional glasses, can improve myopia.

Although still a prototype, the device named Kubota Glasses has shown very promising results in the tests that have been developed.

Myopia is a refractive error in the eyeball that causes an incorrect focus of the images in the eye, i.e. objects focus in front of the retina, blurring the image of distant objects. The development of Kubota Glasses is to passively stimulate the retina in order to correct myopia over time.

According to the company, the goal is to launch the glasses first in Asia. This is because 96% of South Koreans and 95% of Japanese, for example, need to wear glasses so that they can see distant objects. But it is also a global problem, when about 2.56 billion people suffer from nearsightedness, and an exponential increase is predicted, according to one study.

If effective, Kubota Glasses from Kubota Pharmaceutical Holdings could be enough to make many lives easier.

As the company explained, smart glasses project an image of the device’s lens onto the wearer’s retina in order to correct the refractive error that causes myopia. In tests, the company realized that the use of Kubota Glasses can correct vision, being used for 60 to 90 minutes per day.

However, aspects such as the time it takes for the glasses to take effect and the short or long duration of wearing them are still unknown. However, Kubota Pharmaceutical Holdings intends to conduct further testing and trials to clarify these topics.

See Also

The company is very confident about the long-term effectiveness of its smart glasses. In addition to the remaining tests, it has already started a clinical trial in the US involving 25 people.

SUBSCRIBE TO GET OUR NEWSLETTERS:

Scroll To Top

We have detected that you are using AdBlock Plus or other adblocking software which is causing you to not be able to view 360 Mozambique in its entirety.

Please add www.360mozambique.com to your adblocker’s whitelist or disable it by refreshing afterwards so you can view the site.